Loading company…
Sentinal4D develops cancer research technology using AI-driven 3D and 4D cellular profiling.
Founded in 2024 and based in London, Sentinal4D combines deep learning with cellular profiling to support drug discovery in cancers including melanoma, breast, pancreatic, and colorectal cancer, as well as neuroblastoma. It serves pharmaceutical companies and academic research institutions. In December 2024, the company raised pre-seed funding led by Twin Path Ventures and Arben Ventures. Its co-founders are Georgia Mitsi, Chris Bakal, and Matt DeVries.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in